MaxCyte, Inc. · NASDAQ:MXCT
MaxCyte — Investor Presentation (January 2021)
16 slides from MaxCyte's investor presentation, January 2021
Slide 1: Driving the next generation of cell-based therapies
Driving the next generation of cell-based therapies • Doug Doerfler, Chief Executive Officer • Amanda Murphy, CFA, Chief Financial Officer January 2021 • Ron Holtz, CPA, Chief Accounting Officer © 2021 MaxCyte, Inc. All Rights Reserved.
Slide 2: Disclaimer
Disclaimer The content of this document (the “Presentation”) has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging in any investment activity may expose an individual
Slide 3: Global partner of choice for non-viral cell engineering technology
Global partner of choice for non-viral cell engineering technology Market-leading manufacturer of cell engineering enabling technologies based on proprietary flow electroporation (the ExPERT™ platform) • High efficiency, reproducible, scalable non-viral cell engineering system; proprietary platform
Slide 4: Executive leadership with broad depth of experience
Executive leadership with broad depth of experience Doug Doerfler Thomas M. Ross Executive Vice President, Global Sales President and Chief Executive Officer Amanda Murphy, CFA* James Brady, PhD Vice President, Technical Applications Chief Financial Officer and Customer Support Ron Holtz, CPA Steve
Slide 5: The ExPERT Platform - For non-viral cell engineering
ExPERT Instrument Portfolio The ExPERTTM Platform - For non-Viral cell engineering • Based on MaxCyte’s proprietary flow electroporation technology that has been optimized over 20+ years; covered by an extensive patent portfolio • Leverages a fundamental property of cells (the • High Performance • >
Slide 6: ExPERT - A single delivery platform for cell engineering from concept to clinic
ExPERTTM - A single delivery platform for cell engineering from concept to clinic Concept DoE Optimization Verification Phase I Pivotal Validation Approval On-Market Disposables (referred to as processing assemblies) facilitate scale up on same GMP platform o The new ExPERT platform (including instr
Slide 7: MaxCyte: Strength in opportunity from two high-value life science markets
MaxCyte: Strength in opportunity from two high-value life science markets DRUG DISCOVERY & DEVELOPMENT CELL THERAPY - CELLS AS DRUGS CELLS TO DISCOVER DRUGS Blue-chip client base includes 20 of the top 25 and all Licenses granted for 140+ cell therapy programs, 100+ of the top ten global pharma comp
Slide 8: Well-positioned to capitalize on rapidly growing cell therapy market
Well-positioned to capitalize on rapidly growing cell therapy market Key Constraints: • Viral vector availability/development costs Cell Therapy Market Growth • Continuing safety concerns Drivers: • Explosive CAR-T growth • Supply chain challenges • Rapid gene editing adoption • Patient access MaxCy
Slide 9: MaxCyte solution: ExPERT platform is more than just a technology
MaxCyte solution: ExPERT™ platform is more than just a technology Supporting our partners in achieving their goals Enables: Field Support o Accelerated path to the clinic o Reduced program risk Research & Development o Reduced unnecessary cash burn Regulatory o Faster path to key company milestones
Slide 10: Value creation from clinical / commercial licenses
Value creation from clinical / commercial licenses Cumulative Potential Pre-CML Milestones • Partners integrate MaxCyte technology to solve >$950m USD their cell engineering challenges for clinical products • Licensing deals include significant development milestones and high-value participation in
Slide 11: MaxCyte-enabled cell therapy clinical trials
MaxCyte-enabled cell therapy clinical trials GENETIC DISEASES INFECTIOUS DISEASES Sickle Cell Disease HIV Beta Thalassemia SOLID TUMORS HEME MALIGNANCIES Pancreatic Cancer Acute Myeloid Leukemia Ovarian Cancer Acute Lymphoblastic Leukemia Neuroblastoma Chronic Lymphocytic Leukemia/SLL Melanoma Pedia
Slide 12: Financials
y) MAGIK Vie ay Financials
Slide 13: 2020 financial highlights and 2021 outlook
2020 financial highlights and 2021 outlook • Robust revenue growth in full year 2020: $26.2m revenue, 21% yr/yr growth and 15% over 2H 2019 despite a challenging COVID environment • Added four additional strategic license customers in the last 12 months (3 signed in 2020 and one signed in early Janu
Slide 14: Solid five-year financial results
Solid five-year financial results 2015-2020 Revenue Instruments Placed Partnered Programs (USD, 000s) Rapid Growth of Licensed Placements Rapid Growth of Licensed Programs Total Commercial Licenses* 5 Year Revenue CAGR 23% 2020 100+ 140 + 12 2020 400 + 2020 $26,200 2019 70 + 100+ 8 2019 320 + 70 + 2
Slide 15: Summary and outlook for 2021 and beyond
Summary and outlook for 2021 and beyond 2020 Conclusions 2021 Goals 1. Reported 21% revenue growth despite a 1. Accelerate top-line growth challenging COVID environment 2. Complete manufacturing expansion/automation 2. Continued to expand capabilities in 3. Continue to launch new PAs to address cust
Slide 16: Thank You
Thank You ir@maxcyte.com www.MaxCyte.com